Advertisement

Juvenile Spondyloarthropathy

  • David A. Cabral
  • Shirley M. L. Tse

Abstract

Juvenile spondyloarthropathy includes both differentiated and undifferentiated forms. The differentiated forms include juvenile ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and arthritis with inflam-matory bowel disease. Enthesitis-related arthritis (ERA) is now the preferred term for undifferentiated forms of juvenile spondyloar-thropathy. Most juvenile spondyloarthropathy patients present with asymmetric oligoarthritis involving the knee, hip, ankle, tarsal, metatarsophalangeal, or foot interphalan-geal joints. Enthesitis — pain, tenderness, and swelling at the site of attachment of tendon, ligament, or fascia to bone — is the most common feature of juvenile spondyloarthrop-athy. The frequency of this finding has led to the term “ enthesitis-related arthritis” (ERA). Monoarthritis of one of these joints, particularly one of the large ones, is also common disease presentation. Axial involvement seldom begins less than 5 years after the clinical onset of juvenile spondyloarthropathy. Some patients with ERA are at high risk of developing ankylosing spondylitis. These include males, patients who are HLA-B27 (human leukocyte antigen B27) positive, and those with early arthritis of the hips, ankles, or sacroiliac joints. Acute anterior uveitis and inflammatory bowel disease are common extraarticular manifestations of ERA.

Keywords

Inflammatory Bowel Disease Ankylose Spondylitis Human Leukocyte Antigen Juvenile Idiopathic Arthritis Sacroiliac Joint 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Amor B, Dougados M, Mijiyawa M. Criteres de classification des spon-dyloarthropathies. Rev Rhum Mal Osteoartic 1990; 57:85–89PubMedGoogle Scholar
  2. Bennett PH. B. T. New York symposium on population studies in the rheumatic diseases: New diagnostic criteria. Bull Rheum Dis 1967; 17:453–458Google Scholar
  3. Burgos-Vargas R. Ankylosing tarsitis: Clinical features of a unique form of tarsal disease in the juvenile-onset spondyloarthropathies. Arthritis Rheum 1991; 34(Suppl):D196Google Scholar
  4. Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesop-athy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989; 16(2):192–197PubMedGoogle Scholar
  5. Burgos-Vargas R, Naranjo A, Castillo J, Katona G. Ankylosing spon-dylitis in the Mexican Mestizo: Patterns of disease according to age at onset. J Rheumatol 1989; 16:186–191PubMedGoogle Scholar
  6. Burgos-Vargas RC, Gutierrez-Suarez R, Vazquez-Mellado J. Efficacy, safety, and tolerability of Infliximab in Juvenile-onset Spondyloar-thropathies (JO-SpA): Results of the three-month, randomized, double-blind, placebo-controlled trial phase. Arthritis Rheum 2007; 56(9S):319Google Scholar
  7. Cabral, DA, Oen KG, et al SEA syndrome revisited: A longterm fol-lowup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992; 19(8):1282–1285PubMedGoogle Scholar
  8. Cassidy J, Kivlin J, et al Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006; 117(5):1843–1845PubMedCrossRefGoogle Scholar
  9. Dougados M, van der Linden S, et al The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylar-thropathy. Arthritis Rheum 1991; 34(10):1218–1227PubMedCrossRefGoogle Scholar
  10. Flato B, Aasland A, et al Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998; 25(2):366–375PubMedGoogle Scholar
  11. Flato B, Hoffmann-Vold AM, et al Long-term outcome and prognostic factors in enthesitis-related arthritis: A case—control study. Arthritis Rheum 2006; 54(11):3573–3582PubMedCrossRefGoogle Scholar
  12. Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis Jr. JC. Clinical, radiographic, and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: Results from the PSOAS cohort. Ann Rheum Dis 2008; 67:233–237PubMedCrossRefGoogle Scholar
  13. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31(10):2055–2061PubMedGoogle Scholar
  14. Jacobs JC, Berdon ED, Johnston WE. HLA-B27-associated spondy-loarthritis and enthesopathy in childhood: Clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982; 100: 521–528PubMedCrossRefGoogle Scholar
  15. Mielants H, Veys EM, et al Gut inflammation in the spondyloarthropa-thies: Clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 1991; 18(10):1542–1551PubMedGoogle Scholar
  16. Mielants H, Veys EM, et al Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy—a prospective study. J Rheumatol 1993; 20(9): 1567–1572PubMedGoogle Scholar
  17. Minden K, Niewerth M, et al Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46(9):2392–2401PubMedCrossRefGoogle Scholar
  18. Petty RE, Southwood TR, et al Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25(10):1991–1994PubMedGoogle Scholar
  19. Petty RE, Southwood TR, et al International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004; 31(2):390–392PubMedGoogle Scholar
  20. Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982; 25(9):1041–1047PubMedCrossRefGoogle Scholar
  21. Schmeling H, Horneff G. Infliximab in two patients with juvenile anky-losing spondylitis. Rheumatol Int 2004; 24(3):173–176PubMedCrossRefGoogle Scholar
  22. Stone M, Warren RW, et al Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylo-sing spondylitis. Arthritis Rheum 2005; 53(3):445–451PubMedCrossRefGoogle Scholar
  23. Tse SM, Burgos-Vargas R, et al Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52(7):2103–2108PubMedCrossRefGoogle Scholar
  24. Tse SM, Laxer RM, et al Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept. J Rheumatol 2006; 33(6):1186–1188PubMedGoogle Scholar
  25. Tse SML, Burgos-Vargas R, O'Shea F, Inman R, Laxer R. Long term outcome of anti-TNF therapy in juvenile spondyloarthropathy. Arthritis Rheum 2007; 56(9S):898Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • David A. Cabral
    • 1
  • Shirley M. L. Tse
    • 2
  1. 1.British Columbia Children's HospitalPediatricsCanada
  2. 2.University of Toronto/SickKids, RheumatologyTorontoCanada

Personalised recommendations